Literature DB >> 2873741

Coronary heart disease death, nonfatal acute myocardial infarction and other clinical outcomes in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group.

.   

Abstract

The Multiple Risk Factor Intervention Trial was a randomized clinical study to test whether a special-intervention (SI) program aimed at reducing serum cholesterol levels, blood pressure and cigarette smoking would prevent coronary heart disease (CHD) in middle-aged men. The main endpoint reported here is the percentage of participants experiencing first major CHD events (either nonfatal acute myocardial infarction [AMI] or CHD death) during 7 years of follow-up. This outcome was slightly less frequent in the 6,428 SI men than in the 6,438 men assigned to their usual source of care (UC). However, the relative difference--either 1% (95% confidence interval -17% to 16%) or 8% (95% confidence interval -5% to 20%), depending on how AMI was classified--was not statistically significant. Regression analyses within the SI and UC groups suggested that the cholesterol and cigarette smoking interventions reduced the number of first major CHD events: the associations between lowering the levels of these 2 factors and reductions in CHD rates were significant (p less than 0.001) and of the anticipated magnitude. A similar analysis of antihypertensive treatment in the SI group revealed no favorable association between lowering blood pressure and CHD rate, and other subgroup comparisons suggested that a mixture of beneficial and adverse effects may underlie this finding. Thus, the nonsignificant overall UC/SI contrast in CHD rates may reflect a combination of the expected beneficial effects of the cholesterol and smoking interventions with unexpected heterogeneous effects of the antihypertensive intervention. Seven of 8 other prespecified cardiovascular endpoints occurred less frequently among SI than among UC men, the difference being nominally significant (p less than 0.05) for angina pectoris, congestive heart failure and peripheral arterial disease.

Entities:  

Mesh:

Year:  1986        PMID: 2873741     DOI: 10.1016/0002-9149(86)90232-8

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  12 in total

1.  Epidemiologic data and planning mental health services. A tale of two surveys.

Authors:  D Blazer; L George; I Winfield
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  1991-01       Impact factor: 4.328

2.  Lipoprotein particles, insulin, adiponectin, C-reactive protein and risk of coronary heart disease among men with metabolic syndrome.

Authors:  Lewis H Kuller; Gregory Grandits; Jerome D Cohen; James D Neaton; Ronald Prineas
Journal:  Atherosclerosis       Date:  2006-10-02       Impact factor: 5.162

3.  Coronary flow reserve in patients with chest pain and normal coronary arteries.

Authors:  D R Holdright; D C Lindsay; D Clarke; K Fox; P A Poole-Wilson; P Collins
Journal:  Br Heart J       Date:  1993-12

4.  Long-term effect of pindolol on lipids and lipoproteins in men with newly diagnosed hypertension.

Authors:  A Terént; M Ribacke; L A Carlson
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

5.  The serum urate-lowering impact of weight loss among men with a high cardiovascular risk profile: the Multiple Risk Factor Intervention Trial.

Authors:  Yanyan Zhu; Yuqing Zhang; Hyon K Choi
Journal:  Rheumatology (Oxford)       Date:  2010-08-30       Impact factor: 7.580

6.  Relation of heart rate parameters during exercise test to sudden death and all-cause mortality in asymptomatic men.

Authors:  A Selcuk Adabag; Gregory A Grandits; Ronald J Prineas; Richard S Crow; Hanna E Bloomfield; James D Neaton
Journal:  Am J Cardiol       Date:  2008-03-19       Impact factor: 2.778

7.  Accuracy of dobutamine stress echocardiography for the diagnosis of coronary artery stenosis in patients with myocardial infarction: the impact of extent and severity of left ventricular dysfunction.

Authors:  A Elhendy; R T yan Domburg; J R Roelandt; M L Geleijnse; J H Cornel; G M el-Said; P M Fioretti
Journal:  Heart       Date:  1996-08       Impact factor: 5.994

8.  Effect Sizes and Primary Outcomes in Large-Budget, Cardiovascular-Related Behavioral Randomized Controlled Trials Funded by NIH Since 1980.

Authors:  Veronica L Irvin; Robert M Kaplan
Journal:  Ann Behav Med       Date:  2016-02

9.  The independent impact of congestive heart failure status and diuretic use on serum uric acid among men with a high cardiovascular risk profile: a prospective longitudinal study.

Authors:  Devyani Misra; Yanyan Zhu; Yuqing Zhang; Hyon K Choi
Journal:  Semin Arthritis Rheum       Date:  2011-03-24       Impact factor: 5.532

10.  Cardio-metabolic risk prediction should be superior to cardiovascular risk assessment in primary prevention of cardiovascular diseases.

Authors:  Hana Rosolova; Barbora Nussbaumerova
Journal:  EPMA J       Date:  2011-03-05       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.